Tubramak 50/100 Mg 50 mg, 100 mg Tablet
PDF Leaflet Revision Date: 25 April 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of pulmonary multidrug-resistant tuberculosis and multibacillary leprosy.
Dosage (summary)
Adults: 100 mg/day for MDR-TB; 50 mg/day for leprosy. Children: 50 mg/day for leprosy.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Safety in pregnancy not established; avoid breastfeeding due to potential skin discoloration in infants.
Key Drug Interactions
- QT prolonging medicines
- CYP3A substrates
Contraindications
- Hypersensitivity to clofazimine
- QT interval prolongation
Common side effects
- Nausea
- Vomiting
- Abdominal pain
- Skin discoloration
Counselling Points
- Take with food for better absorption
- Importance of adherence to therapy
- Monitor for signs of adverse reactions
Serious warnings
- Risk of QT prolongation
- Gastrointestinal disorders
- Skin discoloration may cause depression
Important Disclaimer
The Tubramak 50/100 Mg 50 mg, 100 mg Tablet professional information leaflet below is the property of Macleods Pharmaceuticals Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
